{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:05:21Z","timestamp":1787011521152,"version":"build-2736575974"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1038\/s41584-023-00991-9","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T16:02:39Z","timestamp":1686844959000},"page":"468-469","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A leading role for interferon as a treatment target in Sj\u00f6gren syndrome"],"prefix":"10.1038","volume":"19","author":[{"given":"Gwenny M.","family":"Verstappen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-0617","authenticated-orcid":false,"given":"Frans G. M.","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"991_CR1","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1093\/rheumatology\/key360","volume":"60","author":"ILA Bodewes","year":"2019","unstructured":"Bodewes, I. L. A., Bj\u00f6rk, A., Versnel, M. A. & Wahren-Herlenius, M. Innate immunity and interferons in the pathogenesis of Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 60, 2561\u20132573 (2019).","journal-title":"Rheumatology (Oxford)"},{"key":"991_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"991_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead096","author":"R Felten","year":"2023","unstructured":"Felten, R. et al. Identification of new candidate drugs for primary Sj\u00f6gren\u2019s syndrome using a drug repurposing transcriptomic approach. Rheumatology (Oxford) https:\/\/doi.org\/10.1093\/rheumatology\/kead096 (2023).","journal-title":"Rheumatology (Oxford)"},{"key":"991_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","volume":"17","author":"GM Verstappen","year":"2021","unstructured":"Verstappen, G. M., Pringle, S., Bootsma, H. & Kroese, F. G. M. Epithelial\u2013immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 17, 333\u2013348 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"991_CR5","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","volume":"60","author":"M Juarez","year":"2021","unstructured":"Juarez, M. et al. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 60, 1364\u20131375 (2021).","journal-title":"Rheumatology (Oxford)"},{"key":"991_CR6","doi-asserted-by":"publisher","first-page":"110302","DOI":"10.1016\/j.celrep.2022.110302","volume":"38","author":"L Yang","year":"2022","unstructured":"Yang, L. et al. Histone deacetylase 3 contributes to the antiviral innate immunity of macrophages by interacting with FOXK1 to regulate STAT1\/2 transcription. Cell Rep. 38, 110302 (2022).","journal-title":"Cell Rep."},{"key":"991_CR7","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1128\/MCB.26.8.3106-3113.2006","volume":"26","author":"I Nusinzon","year":"2006","unstructured":"Nusinzon, I. & Horvath, C. M. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol. Cell. Biol. 26, 3106\u20133113 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"991_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2010.03.019","volume":"52","author":"S Joshi","year":"2010","unstructured":"Joshi, S., Kaur, S., Kroczynska, B. & Platanias, L. C. Mechanisms of mRNA translation of interferon stimulated genes. Cytokine 52, 123\u2013127 (2010).","journal-title":"Cytokine"},{"key":"991_CR9","doi-asserted-by":"publisher","first-page":"681941","DOI":"10.3389\/fimmu.2021.681941","volume":"12","author":"GM Verstappen","year":"2021","unstructured":"Verstappen, G. M. et al. The transcriptome of paired major and minor salivary gland tissue in patients with primary Sj\u00f6gren\u2019s syndrome. Front. Immunol. 12, 681941 (2021).","journal-title":"Front. Immunol."},{"key":"991_CR10","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","volume":"61","author":"E Price","year":"2022","unstructured":"Price, E. et al. Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study. Rheumatology (Oxford) 61, 4797\u20134808 (2022).","journal-title":"Rheumatology (Oxford)"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00991-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00991-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T13:09:38Z","timestamp":1690204178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00991-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-00991-9","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"15 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are co-applicants on an unrestricted grant by AstraZeneca for NCT05383677 (ANISE-II trial). G.M.V. received consultancy fees from Argenx. F.G.M.K. received consultancy fees from ArgenX and Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}